Carisma Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CARM research report →
Companycarismatx.com
Carisma Therapeutics, Inc. , a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases.
- CEO
- Saar Gill
- IPO
- 2014
- Employees
- 46
- HQ
- Philadelphia, PA, US
Price Chart
Valuation
- Market Cap
- $4.18K
- P/E
- 0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.05%
- Op Margin
- 20.61%
- Net Margin
- 15.28%
- ROE
- -28.86%
- ROIC
- -10330.48%
Growth & Income
- Revenue
- $19.63M · 31.59%
- Net Income
- $-60,477,000 · 30.39%
- EPS
- $-1.46 · 43.63%
- Op Income
- $-62,179,000
- FCF YoY
- 27.06%
Performance & Tape
- 52W High
- $1.27
- 52W Low
- $0.00
- 50D MA
- $0.02
- 200D MA
- $0.09
- Beta
- 1.31
- Avg Volume
- 61.55K
Get TickerSpark's AI analysis on CARM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 7, 25 | Klichinsky Michael | other | 56,982 |
| Oct 7, 25 | Klichinsky Michael | sell | 56,982 |
| Oct 7, 25 | Klichinsky Michael | other | 56,982 |
| Oct 1, 25 | Klichinsky Michael | sell | 165,000 |
| Oct 2, 25 | Klichinsky Michael | sell | 200,000 |
| Oct 3, 25 | Klichinsky Michael | sell | 119,347 |
| Jan 28, 25 | Klichinsky Michael | other | 221,000 |
| Jan 28, 25 | Kelly Steven | other | 500,000 |
| Jan 1, 25 | McAndrew Natalie | other | 0 |
| Oct 31, 24 | Cheng Sohanya Roshan | other | 38,700 |
Our CARM Coverage
We haven't published any research on CARM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CARM Report →